202 related articles for article (PubMed ID: 19491324)
1. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.
Caputo A; Hinzpeter A; Caci E; Pedemonte N; Arous N; Di Duca M; Zegarra-Moran O; Fanen P; Galietta LJ
J Pharmacol Exp Ther; 2009 Sep; 330(3):783-91. PubMed ID: 19491324
[TBL] [Abstract][Full Text] [Related]
2. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
Pedemonte N; Sonawane ND; Taddei A; Hu J; Zegarra-Moran O; Suen YF; Robins LI; Dicus CW; Willenbring D; Nantz MH; Kurth MJ; Galietta LJ; Verkman AS
Mol Pharmacol; 2005 May; 67(5):1797-807. PubMed ID: 15722457
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.
Cai Z; Taddei A; Sheppard DN
J Biol Chem; 2006 Jan; 281(4):1970-7. PubMed ID: 16311240
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel.
Pedemonte N; Boido D; Moran O; Giampieri M; Mazzei M; Ravazzolo R; Galietta LJ
Mol Pharmacol; 2007 Jul; 72(1):197-207. PubMed ID: 17452495
[TBL] [Abstract][Full Text] [Related]
5. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
Bompadre SG; Sohma Y; Li M; Hwang TC
J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
Liu X; Dawson DC
Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
[TBL] [Abstract][Full Text] [Related]
7. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein.
Melin P; Thoreau V; Norez C; Bilan F; Kitzis A; Becq F
Biochem Pharmacol; 2004 Jun; 67(12):2187-96. PubMed ID: 15163550
[TBL] [Abstract][Full Text] [Related]
8. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
9. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
[TBL] [Abstract][Full Text] [Related]
10. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
11. Influence of cell background on pharmacological rescue of mutant CFTR.
Pedemonte N; Tomati V; Sondo E; Galietta LJ
Am J Physiol Cell Physiol; 2010 Apr; 298(4):C866-74. PubMed ID: 20053923
[TBL] [Abstract][Full Text] [Related]
12. Converting nonhydrolyzable nucleotides to strong cystic fibrosis transmembrane conductance regulator (CFTR) agonists by gain of function (GOF) mutations.
Okeyo G; Wang W; Wei S; Kirk KL
J Biol Chem; 2013 Jun; 288(24):17122-33. PubMed ID: 23620589
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
14. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
15. The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B.
Melin P; Norez C; Callebaut I; Becq F
J Membr Biol; 2005 Dec; 208(3):203-12. PubMed ID: 16604470
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
17. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
18. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
19. Current development of CFTR potentiators in the last decade.
Spanò V; Venturini A; Genovese M; Barreca M; Raimondi MV; Montalbano A; Galietta LJV; Barraja P
Eur J Med Chem; 2020 Oct; 204():112631. PubMed ID: 32898816
[TBL] [Abstract][Full Text] [Related]
20. On the interactions between nucleotide binding domains and membrane spanning domains in cystic fibrosis transmembrane regulator: A molecular dynamic study.
Belmonte L; Moran O
Biochimie; 2015 Apr; 111():19-29. PubMed ID: 25640670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
